Researchers at Karolinska Institutet have established a novel transplantation site for islets of Langerhans that enables long-term intravital microscopy of islet physiology in awake mice with ...
Allo-Evasion™ 5.0-engineered iPSC beta islets are designed to overcome immune rejection and provide durable glucose control without chronic immunosuppression Compelling preclinical data demonstrate ...
Borrowing a cancer cell’s disguise, scientists shielded insulin-producing cells from attack by the immune system, a breakthrough that could pave the way for targeted type 1 diabetes treatments without ...
For the first time, researchers have transplanted gene-edited donor islet cells that secrete insulin in a person with type 1 diabetes (T1D) without the use of immunosuppression. The study subject, a ...
Tegoprubart to be Used as Immunosuppressive Agent in Cohort C of Sernova’s Phase 1/2 Cell Pouch Bio-hybrid Organ Clinical Trial in Patients with Type 1 Diabetes LONDON, Ontario, July 09, 2025 (GLOBE ...
In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) restored insulin production and ended severe hypoglycemia in adults with type 1 ...
Can we predict—and prevent—why transplanted beta cells fail? A preclinical study titled “ChemPerturb-seq screen identifies a small molecule cocktail enhancing human beta cell survival after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback